Related Experiment Videos
Intraventricular administration of amikacin for complicated Gram-negative meningitis and ventriculitis
Abstract:
Four pediatric neurosurgical patients with Gram-negative meningitis and ventriculitis were treated with parenteral and intraventricular amikacin, a new aminoglycoside. The organisms infecting these patients were resistant to multiple antimicrobial drugs but were sensitive to amikacin. Treatment was continued for 14 days after cerebrospinal fluid cultures became negative. All four patients were cured and have demonstrated no nephrotoxicity, ototoxicity, or evidence of persistent infection on follow-up examination.
Insights
This study shows amikacin effectively treated Gram-negative meningitis and ventriculitis in pediatric neurosurgery patients. The new aminoglycoside cured all patients without causing harmful side effects.
Area of Science:
- Neuroscience
- Infectious Diseases
- Pharmacology
Background:
- Gram-negative meningitis and ventriculitis pose significant challenges in pediatric neurosurgery.
- Multidrug-resistant organisms complicate treatment options for these severe infections.
Observation:
- Four pediatric neurosurgical patients presented with Gram-negative meningitis and ventriculitis.
- Cultures revealed organisms resistant to multiple antibiotics but susceptible to amikacin.
Findings:
- Treatment involved parenteral and intraventricular administration of amikacin.
- All four patients achieved a cure after 14 days of treatment post-negative cultures.
- No evidence of nephrotoxicity or ototoxicity was observed during follow-up.
Implications:
- Amikacin offers a promising therapeutic option for multidrug-resistant Gram-negative meningitis/ventriculitis in pediatric neurosurgery.
- This highlights the potential of novel aminoglycosides in combating challenging CNS infections.
- Further research into amikacin's efficacy and safety in pediatric neuro-infectious diseases is warranted.